CRISPR Therapeutics: Buy The Secondary – Seeking Alpha
Seeking Alpha |
CRISPR Therapeutics: Buy The Secondary
Seeking Alpha A major milestone was achieved when they submitted their CTA for CTX001 in β-thalassemia. Preclinical data provides rationale for ushering the program forward and their CAR-T efforts should not be overlooked. Readers who have done their due diligence … Microsoft to use artificial intelligence to improve CRISPR After Reaching 52-Week High, Is CRISPR Therapeutics AG (CRSP)'s Near-Term Analysis Positive? Gene editing could be the future, but doctors think humans might be immune to it |
